|
|
|
||
|
|
||
|
||
| Title: | Thalidomide With Doxil, Vincristine, and Decadron (DVD-T) for Newly Diagnosed & Relapsed/Refractory Multiple Myeloma |
|---|---|
|
|
| Phase: | II |
|
|
| Purpose: | To determine the effectiveness of thalidomide, Doxil®, vincristine, and Decadron® in treating patients with multiple myeloma |
|
|
| Eligibility: |
|
|
|
| Treatment: | Patients receive oral thalidomide every day beginning day 1; Doxil and vincristine via IV on day 1, and oral Decadron on days 1 through 4 of each treatment cycle. (1 cycle = 4 weeks). The study continues for a minimum of 6 treatment cycles. After treatment cycles end, thalidomide continues at the highest-tolerated dose every day, and prednisone begins every other day as maintenance therapy |
|
|
| Contact: |
Ohio Cleveland Clinic Mary Ann Karam 216-445-1232 |
|
|
| Please note: the trials indicated do not include the full inclusion or exclusion criteria. For full protocols, please contact the Principal Investigator (PI) listed. |
|
|
|
|
|
|
Related Links
|